Pacific Biosciences of California, Inc. (PACB) Dividend History

Pacific Biosciences of California, Inc. develops and commercializes advanced DNA sequencing systems and technologies. Known for its long-read sequencing capabilities, the company provides solutions for genomic research, clinical applications, and agricultural research, enabling detailed and accurate analysis of complex genetic structures.

1305 O'Brien Drive, Menlo Park, CA, 94025
Phone: 650-521-8000
Website: https://www.pacb.com

Dividend History

Pacific Biosciences of California, Inc. currently does not pay dividends

Company News

  • The long-read sequencing market is projected to grow significantly, driven by the increasing adoption of next-generation sequencing technologies in genomic research, precision medicine, and genetic disease diagnostics. The U.S. market is expected to surge, benefiting from federal funding and a well-established infrastructure supporting these applications.

    GlobeNewswire Inc.
    Featured Companies: ILMN
  • Ark Invest has been adding to its positions in Amazon, GitLab, and Pacific Biosciences of California. Amazon's stock hit an all-time high last month, and analysts see further upside. GitLab's recent financial results exceeded expectations, while Pacific Biosciences has struggled but Ark remains a believer in its long-term potential.

    The Motley Fool
    Featured Companies: AMZN GTLB
  • Cathie Wood, the famed investor, is doubling down on her conviction bets in biotechnology, artificial intelligence, and electric vehicles, including Tesla, Pacific Biosciences, and Crispr Therapeutics.

    Investing.com
    Featured Companies: CRSP
  • PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.

    Zacks Investment Research
    Featured Companies: DVA ECL UHS
  • Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on Pacific Biosciences (NASDAQ:PACB) in the last three months. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 2 6 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 3 0 0 2M Ago 2 2 3 0 0 3M Ago 0 0 0 0 0 Analysts have set 12-month price targets for Pacific Biosciences, revealing an average target of $3.64, a high estimate of $8.00, and a low estimate of $2.00. A decline of 57.92% from the prior average price target is evident in the current average. Diving into Analyst Ratings: An In-Depth Exploration The analysis of recent analyst actions sheds light on the perception of Pacific Biosciences by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Tycho Peterson Jefferies Announces Buy $4.00 - Tejas Savant Morgan Stanley Lowers Equal-Weight $4.00 $10.00 David Westenberg Piper Sandler Lowers Neutral $2.00 $6.50 Luke Sergott Barclays Lowers Equal-Weight $2.00 $3.00 Matthew Sykes Goldman Sachs Lowers Neutral $2.50 $7.00 Eve Burstein Bernstein Lowers Outperform $2.50 $9.00 Matthew Sykes Goldman Sachs Lowers Neutral $2.50 $7.00 Sung Ji Nam Scotiabank Lowers Sector Outperform $8.00 $15.00 Daniel Brennan TD Cowen Lowers Buy $2.50 $12.00 Luke Sergott Barclays Lowers Equal-Weight $3.00 $8.00 Matthew Sykes Goldman Sachs Lowers Buy $7.00 $9.00 Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Pacific Biosciences. This ...Full story available on Benzinga.com

    Benzinga
Page data last updated 07/23/2025 02:55:40 UTC